OP 2102
Alternative Names: OP-2102Latest Information Update: 02 Aug 2022
At a glance
- Originator OrchestratePharma
- Class Sleep disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Sleep disorders
Most Recent Events
- 26 Jul 2022 Early research in Sleep disorders in Switzerland (unspecified route), prior to July 2022 (Orchestrate Pharma pipeline, July 2022)